BND-22, a first-in-class humanized ILT2-blocking antibody, promotes antitumor immunity and tumor regression.
Mandel I, Haves Ziv D, Goldshtein I, Peretz T, Alishekevitz D, Fridman Dror A, Hakim M, Hashmueli S, Friedman I, Sapir Y, Greco R, Qu H, Nestle F, Wiederschain D, Pao L, Sharma S, Ben Moshe T.
Mandel I, et al. Among authors: ben moshe t.
J Immunother Cancer. 2022 Sep;10(9):e004859. doi: 10.1136/jitc-2022-004859.
J Immunother Cancer. 2022.
PMID: 36096532
Free PMC article.